# Biogen

Biogen is a Corporate Investor based in Cambridge, United States.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** 225 Binney Street, Cambridge, MA 02142, United States
- **Founded:** 1978
- **Assets under management:** Undisclosed
- **Website:** biogen.com
- **LinkedIn:** https://www.linkedin.com/company/biogen-
- **Wikidata:** Q864338

## Regulatory record

- **Reports private funds:** No

## About

Biogen creates medicines for hard-to-treat diseases. The company uses cutting-edge science to develop potential breakthrough therapies in neurology, immunology, and rare diseases. Scientific curiosity and aspirations to help people around the world are at the core of its legacy and vision for the future.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- 75 Broadway, Cambridge, MA
- 115 Broadway, Cambridge, MA
- 300 Binney Street, Cambridge, MA
- 133 Boston Post Road, Weston, MA

## People

- Christopher Viehbacher — President and Chief Executive Officer
- Phillip Sharp — Co-founder
- Walter Gilbert — Co-founder

## Questions

### Who runs Biogen's venture investing?

Corporate venture investing at Biogen is conducted through Biogen New Ventures, led by Chelsea Johnson as Head of Biogen New Ventures. She reports within the corporate development structure, which ultimately falls under CEO Christopher Viehbacher. The unit operates with a mandate to make strategic minority equity investments aligned with the parent company's R&D priorities.

### Does Biogen make fund commitments or only direct investments?

Biogen New Ventures makes direct minority equity investments rather than participating as a limited partner in external venture funds. The unit's purpose — gaining visibility into adjacent science and securing future partnering or acquisition optionality — is best served by direct stakes. There is no public record of the firm acting as an LP in biotechnology venture capital funds.

### Which therapeutic areas does Biogen invest in?

Investments cluster around the parent company's strategic interests: multiple sclerosis, Alzheimer's disease and neurodegeneration, neuromuscular disease, neuropsychiatry, and immunology. Rare genetic diseases of the central nervous system form a secondary focus. The firm explicitly avoids oncology, metabolic disease, and cardiovascular biotechnology, where it has no pipeline programs.

### What is the relationship between Biogen's venture arm and its R&D budget?

Biogen New Ventures sits within the broader corporate development function and draws its capital allocation from the parent company's balance sheet, not from a ring-fenced venture fund. The parent spent roughly $2.2 billion on research and development in 2022 (per company filings), and venture equity investments represent a small fraction of that total, functioning as an external-innovation supplement rather than an independent return-seeking pool.

## Related profiles

- [Bio-1](https://altss.com/profile/bio-1)
- [BIP Wealth](https://altss.com/profile/bip-wealth)

---

Last updated: 2026-08-11T15:06:13.093Z

Canonical page: https://altss.com/profile/biogen

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology